The N342S MYLIP polymorphism is associated with high total cholesterol and increased LDL receptor degradation in...

Area of Science:

• Genetics
• Cardiovascular Medicine
• Biochemistry

Background:

• Atherosclerotic cardiovascular disease (ASCVD) impacts a significant portion of the adult population.
• Hypercholesterolemia, a key risk factor for ASCVD, is often inadequately managed with current therapies.
• The myosin regulatory light chain-interacting protein (MYLIP) is a known regulator of the LDL receptor (LDLR) pathway.

Purpose of the Study:

• To identify functional genetic variants in the MYLIP gene associated with LDL-cholesterol (LDL-C) levels.
• To investigate the role of these variants in a population distinct from previous genome-wide association studies (GWASs).
• To elucidate the functional mechanism by which MYLIP variants influence LDL-C metabolism.

Main Methods:

• Analysis of a Mexican population to fine-map susceptibility variants.
• Identification and characterization of the nonsynonymous SNP rs9370867.
• Functional studies including mutagenesis and assessment of LDLR degradation and LDL uptake.

Main Results:

• The nonsynonymous SNP rs9370867 (encoding N342S) in MYLIP was identified as a functional variant associated with high total cholesterol in a Mexican population.
• The Asn-encoding allele of rs9370867 was linked to increased LDLR degradation and reduced LDL uptake.
• Mutagenesis at residue 342 demonstrated its critical role in MYLIP-mediated LDLR targeting, without affecting intrinsic E3 ligase activity.

Conclusions:

• MYLIP activity significantly influences LDL-C levels.
• Pharmacologic inhibition of MYLIP presents a potential therapeutic strategy for managing dyslipidemia and ASCVD.
• Understanding MYLIP's role in LDLR regulation offers new avenues for treating cholesterol disorders.